Xiaflex Risk/Benefit Profile Acceptable Despite Tendon Ruptures, Auxilium Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III data supports Xiaflex injection as alternative to surgery for treating Dupuytren’s contracture.
You may also be interested in...
Auxilium Submits Xiaflex BLA, Scans Wide-Open Orphan Market
Niche indications in Dupuytren’s and Peyronie’s could pay off for Auxilium and partner Pfizer.
Auxilium Submits Xiaflex BLA, Scans Wide-Open Orphan Market
Niche indications in Dupuytren’s and Peyronie’s could pay off for Auxilium and partner Pfizer.
Pfizer And Auxilium Set Partnership For European Rights To Xiaflex
For $75 million upfront plus milestones and royalties, Pfizer gets Xiaflex rights for two indications in 46 countries.